Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jens Wenkel"'
Publikováno v:
Expert Opinion on Biological Therapy. 2:671-676
The 93rd Annual Meeting of the American Association of Cancer Research was held in San Francisco, CA, USA. It was one of the largest conferences of its kind covering all aspects of cancer research with ∼ 6000 scientific presentations over a period
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70bc96724daf69686bbb477ea42c74aa
https://doi.org/10.1517/14712598.2.6.671
https://doi.org/10.1517/14712598.2.6.671
Autor:
Yan Zeng, Rong Xiang, Gerhard Gaedicke, Jens Wenkel, Holger N. Lode, Jikai Jiang, Nicole Huebener
Publikováno v:
Cancer letters. 228(1-2)
The induction of tumor protective immunity against neuroblastoma remains a major challenge for active immunotherapy. Fractalkine is a unique Th1 CX3C chemokine known to induce adhesion and migration of leukocytes mediated by both, a membrane-bound an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::178b54099edad712122dfe8a69861ff4
https://pubmed.ncbi.nlm.nih.gov/15953676
https://pubmed.ncbi.nlm.nih.gov/15953676
Autor:
Nicole Huebener, Gerhard Gaedicke, A Strandsby, B Lange, Ulrike Schroeder, Jens Wenkel, J Jikai, Holger N. Lode, Wolfgang Wrasidlo
Publikováno v:
Cancer letters. 197(1-2)
Effective chemotherapy in neuroblastoma is limited by poor anti-tumor efficacy, systemic toxicity and the induction of drug resistance. Here, we provide further evidence that a hydrolytic activated prodrug design may overcome these problems. For this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8966b2b6007aba170339b30854d9fb87
https://pubmed.ncbi.nlm.nih.gov/12880986
https://pubmed.ncbi.nlm.nih.gov/12880986
Autor:
Jens Wenkel, Kathrin M. Bernt, Andreas G. Niethammer, Lueder Wiebusch, Ralph A. Reisfeld, Christian Hagemeier, Roey J. Amir, Gerhard Gaedicke, Bjoern Lange, Ulrike Schroeder, Jiang Jikai, Holger N. Lode, Nicole Huebener, Wolfgang Wrasidlo, Doron Shabat
Publikováno v:
Blood. 102(1)
Effective therapy of high-risk leukemia with established cytotoxic drugs may be limited by poor antitumor efficacy, systemic toxicity, and the induction of drug resistance. Here, we provide the first evidence that hydrolytically activated prodrugs ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ec5f8d64f5237038d9ced64aab0b86
https://pubmed.ncbi.nlm.nih.gov/12623853
https://pubmed.ncbi.nlm.nih.gov/12623853